MedTrace Logo

The Diagnosis and Prognosis of Nonpalpable Breast Cancer Detected by the US vs Mammography: a Clinical Noninferiority Trial.

NCT04360616 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1277

Last updated 2022-01-25

No results posted yet for this study

Summary

To evaluate and compare the sensitivity, specificity, AUC, pathology results of core needle biopsy and surgical pathology results coincidence rate, tumor staging, and DFS (disease-free survival) of US-detected nonpalpable breast cancer vs mammography-detected nonpalpable breast cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

imaging

perform US and mammography examination

Sponsors & Collaborators

  • The First Affiliated Hospital of the Fourth Military Medical University

    lead OTHER

Principal Investigators

  • Hongping Song, MD · Xijing hospital of The fourth military medical university

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04360616 on ClinicalTrials.gov